Lonza Expands Conjugation Facility with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide development and manufacturing capacity for pre-clinical to commercial supply
1500m
2 of manufacturing space will include two additional production suites in addition to the necessary manufacturing-related infrastructure
A significant increase of process and analytical development capacity will enable Lonza to offer expertise to a broad customer base
Quote from Iwan Bertholjotti, Director Commercial Development Bioconjugates, Lonza:
'Lonza started to offer CDMO services for antibody-drug conjugates (ADCs) back in 2006 and we now manufacture the majority of the currently commercially approved ADCs. The field goes beyond ADC's and Lonza has the expertise to support customers bringing a range of different bioconjugates to market. The latest investment in additional bioconjugation development and manufacturing capacity is well aligned with other current investments in monoclonal antibodies and small molecules within the Lonza network. Together they further extend our offer of a reliable and integrated supply solution for an expanding class of innovative therapies.'